FDA Advisers Vote Against PTSD Combo Treatment

Published on July 18, 2025

The U.S. Food and Drug Administration’s panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma’s drug when used in combination with Viatris’ Zoloft for the treatment of adults with PTSD. The panel voted 10-1 to say the available data does not…

Read Full Article (External Site)